Potential clinical utility of dual time point FDG-PET for distinguishing benign from malignant lesions: implications for oncological imaging

Revista Espanola de Medicina Nuclear

Volumn 28, Issue 3, 2009, Pages 159-166

  Sanz Viedma, S ^a   Torigian, D A ^a   Parsons, M ^a   Basu, S ^a   Alavi, A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ARTICLE; BREAST CANCER; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DRUG ACCUMULATION; DRUG UPTAKE; FALSE POSITIVE RESULT; HEAD AND NECK TUMOR; HISTOPATHOLOGY; HUMAN; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NODULE; LUNG SQUAMOUS CELL CARCINOMA; MASTECTOMY; NEOPLASM; NONHUMAN; PARTIAL MASTECTOMY; POSITRON EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; TUMOR DIFFERENTIATION;

ANIMALS; BREAST DISEASES; BREAST NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; LUNG DISEASES; LUNG NEOPLASMS; MALE; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 67649200379     PISSN: 02126982     EISSN: 1578200X     Source Type: Journal    
DOI: 10.1016/S0212-6982(09)71360-6     Document Type: Article

References (32)

1. Hustinx R., Bénard F., and Alavi A. Whole-body FDG-PET imaging in the management of patients with cancer. Semin Nucl Med 32 (2002) 35-46
2. El-Haddad G., Zhuang H., Gupta N., and Alavi A. Evolving role of positron emission tomography in the management of patients with inflammatory and other benign disorders. Semin Nucl Med 34 (2004) 313-329
3. Basu S., and Alavi A. Partial volume correction of standardized uptakevalues and the dual time point in FDG-PET imaging: should these be routinely employed in assessing patients with cancer?. Eur J Nucl Med Mol Imaging 34 (2007) 1527-1529
4. Kim C.K., Gupta N.C., Chandramouli B., and Alavi A. Standardized uptake values of FDG: body surface area correction is preferable to body weight correction. J Nucl Med 35 (1994) 164-167
5. Basu S., Zaidi H., Houseni M., Bural G., Udupa J., Acton P., et al. Novel quantitative techniques for assessing regional and global function and structure based on modern imaging modalities: implications for normal variation, aging and diseased states. Semin Nucl Med 37 (2007) 223-239
6. Hickeson M., Yun M., Matthies A., Zhuang H., Adam L.E., Lacorte L., et al. Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nodules on FDG-PET. Eur J Nucl Med Mol Imaging 29 (2002) 1639-1647
7. de Geus-Oei L.F., van Krieken J.H., Aliredjo R.P., Krabbe P.F., Frielink C., Verhagen A.F., et al. Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer 55 (2007) 79-87
8. Pauwels E.K., Ribeiro M.J., Stoot J.H., McCready V.R., Bourguignon M., and Mazière B. FDG accumulation and tumor biology. Nucl Med Biol 25 (1998) 317-322
9. Gallagher B.M., Fowler J.S., Gutterson N.I., MacGregor R.R., Wan C.N., and Wolf A.P. Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. J Nucl Med 19 (1978) 1154-1161
10. Zhuang H., Pourdehnad M., Lambright E.S., Yamamoto A.J., Lanuti M., Li P., et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 42 (2001) 1412-1417
11. Álvarez R.M., Borrego I., Ruiz J.V., and Vázquez R.J. Evaluation of efficacy and clinical impact of positron emission tomographywith 18F fluoro-deoxyglucose in patients with suspicion of recurrent head and neck cancer or distant metastases. Rev Esp Med Nucl 26 (2007) 30-39
12. Basu S., and Alavi A. Defining co-related parameters between 'metabolic' flare and 'clinical', 'biochemical', and 'osteoblastic' flare and establishing guidelines for assessing response to treatment in cancer. Eur J Nucl Med Mol Imaging 34 (2007) 441-443
13. Hustinx R., Smith R.J., Benard F., Rosenthal D.I., Machtay M., Farber L.A., et al. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med 26 (1999) 1345-1348
14. 18Fluorodeoxyglucose positron emission tomography, a standard diagnostic tool in lung cancer. J Natl Cancer Inst 99 (2007) 1741-1743
15. 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med 43 (2002) 871-875
16. Xiu Y., Bhutani C., Dhurairaj T., Yu J.Q., Dadparvar S., Reddy S., et al. Dual-time point FDG PET imaging in the evaluation of pulmonary nodules with minimally increased metabolic activity. Clin Nucl Med 32 (2007) 101-105
17. Basu S., Kung J., Houseni M., Zhuang H., Tidmarsh G.F., and Alavi A. Temporal profile of fluorodeoxyglucose uptake in malignant lesions and normal organs over extended time periods in patients with lung carcinoma: implications for its utilization in assessing malignant lesions. Q J Nucl Med Mol Imaging 12 (2008) 1-8
18. Mavi A., Urhan M., Yu J.Q., Zhuang H., Houseni M., Cermik T.F., et al. Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes. J Nucl Med 47 (2006) 1440-1446
19. Kumar R., Zhuang H., Schnall M., Conant E., Damia S., Weinstein S., et al. FDG PET positive lymph nodes are highly predictive of metastasis in breast cancer. Nucl Med Commun 27 (2006) 231-236
20. Rosen E.L., Eubank W.B., and Mankoff D.A. FDG PET, PET/CT, and breast cancer imaging. Radiographics 27 (2007) 215-229
21. Kumar R., Loving V.A., Chauhan A., Zhuang H., Mitchell S., and Alavi A. Potential of dualtime-point imaging to improve breast cancer diagnosis with(18)F-FDG PET. J Nucl Med 46 (2005) 1819-1824
22. Mavi A., Cermik T.F., Urhan M., Puskulcu H., Basu S., Yu J.Q., et al. The effects of estrogen, progesterone, and C-erbB-2 receptor states on 18F-FDG uptake of primary breast cancer lesions. J Nucl Med 48 (2007) 1266-1272
23. Basu S., Chen W., Tchou J., Mavi A., Cermik T., Czerniecki B., et al. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer 112 (2008) 995-1000
24. Basu S., Mavi A., Cermik T., Houseni M., and Alavi A. Implications of standardized uptake value measurements of the primary lesions in proven cases of breast carcinoma with different degree of disease burden at diagnosis: does 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography predict tumor biology?. Mol Imaging Biol 10 (2008) 62-66
25. Ma S.Y., See L.C., Lai C.H., Chou H.H., Tsai C.S., Ng K.K., et al. Delayed (18)F-FDG PET for detection of para-aortic lymph node metastases in cervical cancer patients. J Nucl Med 44 (2003) 1775-1783
26. Nishiyama Y., Yamamoto Y., Fukunaga K., Kimura N., Miki A., Sasakawa Y., et al. Dualtime-point 18F-FDG PET for the evaluation of gallbladder carcinoma. J Nucl Med 47 (2006) 633-638
27. Nakamoto Y., Higashi T., Sakahara H., Tamaki N., Kogire M., Doi R., et al. Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer 89 (2000) 2547-2554
28. Spence A.M., Muzi M., Mankoff D.A., O'Sullivan S.F., Link J.M., Lewellen T.K., et al. 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter. J Nucl Med 45 (2004) 1653-1659
29. Houseni M., Chamroonrat W., Bural G., Yang H., El-Haddad G., Acikgoz G., et al. Promising role of dual time FDG-PET imaging in assessing focal and diffuse bone marrow disorders. J Nucl Med 47 (2006) 227
30. Wehrli N.E., Bural G., Houseni M., Alkhawaldeh K., Torigian D.A., and Alavi A. Determination of age-related changes in structure and function of skin, adipose tissue, and skeletal muscle with computed tomography, magnetic resonance imaging, and positron emission tomography. Semin Nucl Med 37 (2007) 195-205
31. Döbert N., Hamscho N., Menzel C., Neuss L., Kovács A.F., and Grünwald F. Limitations of dual time point FDG-PET imaging in the evaluation of focal abdominal lesions. Nuklearmedizin 43 (2004) 143-149
32. Garrastachu P., García-Velloso M.J., Domínguez I., Martino E., Espinos J., Peñuelas I., et al. Dual-time point FDG imaging greatly improves the diagnosis of incidental uptake in the abdomino-pelvic area. J Nucl Med 49 (2008) 350P